Matrix metalloproteinases and the thyroid

Thyroid

Volumn 10, Issue 12, 2000, Pages 1061-1069

  Kraiem, Z ^a   Korem, S ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; PROTEINASE;

BASEMENT MEMBRANE; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; REVIEW; THYROID GLAND; TUMOR GROWTH;

EID: 0034501336     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2000.10.1061     Document Type: Review

References (103)

1. Matrix metalloproteinases: Multifunctional contributors to tumor progression
2. Matrix metalloproteinases and metastasis
3. Regulation of matrix metalloproteinase expression in tumor invasion
4. Matrix metalloproteinases in tumour invasion and metastasis
5. Matrix metalloproteinases
6. Matrix metalloproteinases
7. Comparative genomic hybridization and chromosomal instability in solid tumours
8. Regulation and function of the JNK subgroup of MAP kinases
9. Mitogen-activated protein kinase pathways
10. Signal transduction through MAP kinase cascades
11. Matrix metalloproteinases: A review
12. Structural biochemistry and activation of matrix metalloproteases
13. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis
14. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2
15. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
16. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas
17. Matrix metalloproteinases: Structure, evolution, and diversification
18. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study
19. Membrane-type metalloproteinases in tumor invasion
20. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
21. Protein, structure mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1
22. Changing views of the role of matrix metalloproteinases in metastasis
23. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
24. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension
25. Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression
26. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
27. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
28. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
29. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy
30. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity, on Swiss 3T3 cells
31. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells
32. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro
33. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases
34. TIMP-2, a growth-stimulatory protein from SV40-transformed human fibroblasts
35. Cell growth-promoting activity, of tissue inhibitor of metalloproteinases-2 (TIMP-2)
36. TIMP-2 growth-stimulatory activity: A concentration- and cell type-specific response in the presence of insulin
37. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity
38. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1
39. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1
40. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induced apoptosis in melanoma cells
41. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis
42. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3
43. Degradation of interleukin 1 beta by matrix metalloproteinases
44. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
45. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures
46. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3
47. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications
48. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation
49. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions
50. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas
51. Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients
52. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression
53. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies
54. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours
55. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer
56. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases
57. Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas
58. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis
59. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer
60. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
61. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: A review
62. Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin
63. A matrix metalloproteinase expressed on the surface of invasive tumour cells
64. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells
65. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro
66. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation
67. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta 1 release
68. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
69. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
70. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
71. TIMP-2 expression modulates human melanoma cell adhesion and motility
72. Matrix metalloproteinases and their inhibitors in tumor growth and invasion
73. On the functional importance of thyrotropin receptor intramolecular cleavage
74. Post-translational processing of the natural human thyrotropin receptor: Demonstration of more than two cleavage sites
75. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain
76. Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases
77. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer
78. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients
79. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: Role of the plasmin activation system
80. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas
81. Enhanced production of matrix metalloproteinase and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas
82. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
83. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis
84. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue
85. Stromal fibroblasts adjacent to invasive thyroid tumors: Expression of gelatinase A but not stromelysin 3 mRNA
86. Human thyroid carcinoma cell lines and normal thyrocytes: Expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein
87. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines
88. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
89. Fibroblasts surrounding melanoma express elevated levels of matrix metalloproteinase-1 (MMP-1) and intercellular adhesion molecule-1 (ICAM-1) in vitro
90. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer
91. Self-regulation of type I collagen degradation by collagen-induced production of matrix metalloproteinase-1 on cholangiocarcinoma and hepatocellular carcinoma cells
92. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo
93. Expression of MMP-1 in the capsule of thyroid cancer - Relationship with invasiveness
94. Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells
95. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro
96. The protein kinase A pathway inhibits c-jun and c-fos proto-oncogene expression induced by the protein kinase C and tyrosine kinase pathways in cultured human thyroid follicles
97. Phenotypic alterations in fos-transgenic mice correlate with changes in Fos/Jun-dependent collagenase type I expression. Regulation of mouse metalloproteinases by carcinogens, tumor promoters, cAMP, and Fos oncoprotein
98. Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC- rather than PKA-activation
99. Coordinate regulation of matrix metalloproteases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts
100. 1 inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts
101. Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells
102. Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors